Metabolic syndrome (MS) is associated with an increased risk of more aggressive prostate cancer (PCa), according to researchers in Spain.
In a study of 2,408 men who underwent prostatic biopsies, Juan Morote, MD, of Vall d’Hebron Hospital and Research Institute, and his co-investigators observed no significant difference in the detection rate of PCa overall between men with MS and those without it (34.5% and 36.4%, respectively), according to a online report in BJU International.
They did find, however, that patients with MS had a significantly higher rate of high-grade PCa (Gleason score 8-10) than those without MS (35.9% vs. 23.9%). Multivariate analyses confirmed that MS was not associated with the risk of PCa, but was associated with a significant 75% increased risk of high-grade tumors.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.